Advertisement

Measles pp 173-189 | Cite as

Measles Control and the Prospect of Eradication

  • W. J. MossEmail author
Chapter
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 330)

Remarkable progress has been made in reducing measles incidence and mortality as a consequence of implementing the measles mortality reduction strategy of the World Health Organization (WHO) and United Nations Children's Fund (UNICEF). The revised global measles mortality reduction goal set forth in the WHO-UNICEF Global Immunization Vision and Strategy for 2006–2015 is to reduce measles deaths by 90% by 2010 compared to the estimated 757,000 deaths in 2000. The possibility of measles eradication has been discussed for almost 40 years, and measles meets many of the criteria for eradication. Global measles eradication will face a number of challenges to achieving and sustaining high levels of vaccine coverage and population immunity, including population growth and demographic changes, conflict and political instability, and public perceptions of vaccine safety. To achieve the measles mortality reduction goal, continued progress needs to be made in delivering measles vaccines to the world's children.

Keywords

Measle Vaccine Measle Vaccination Polio Eradication Population Immunity Measle Case 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Amanna IJ, Carlson NE, Slifka MK (2007) Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 357:1903–1915PubMedCrossRefGoogle Scholar
  2. Andrews N, Tischer A, Siedler A, Pebody RG, Barbara C, Cotter S, Duks A, Gacheva N, Bohumir K, Johansen K, Mossong J, Ory F, Prosenc K, Slacikova M, Theeten H, Zarvou M, Pistol A, Bartha K, Cohen D, Backhouse J, Griskevicius A (2008) Towards elimination: measles susceptibility in Australia and 17 European countries. Bull World Health Organ 86:197–204PubMedCrossRefGoogle Scholar
  3. Angel JB, Walpita P, Lerch RA, Sidhu MS, Masuredar M, DeLellis RA, Noble JT, Snydman DR, Udem SA (1998) Vaccine-associated measles pneumonitis in an adult with AIDS. Ann Intern Med 129:104–106PubMedGoogle Scholar
  4. Bellini WJ, Helfand RF (2003) The challenges and strategies for laboratory diagnosis of measles in an international setting. J Infect Dis 187 [Suppl 1]:S283–S290PubMedCrossRefGoogle Scholar
  5. Biellik R, Madema S, Taole A, Kutsulukuta A, Allies E, Eggers R, Ngcobo N, Nxumalo M, Shearley A, Mabuzane E, Kufa E, Okwo-Bele JM (2002) First 5 years of measles elimination in southern Africa: 1996–2000. Lancet 359:1564–1568PubMedCrossRefGoogle Scholar
  6. Centers for Disease Control (1997) Measles eradication: recommendations from a meeting cosponsored by the World Health Organization, the Pan American Health Organization, and the CDC. MMWR 46:1–20Google Scholar
  7. Centers for Disease Control (2000) Measles outbreak—Netherlands, April 1999 – January 2000. MMWR Morb Mortal Wkly Rep 49:299–303Google Scholar
  8. Centers for Disease Control and Prevention (2005) Global Measles and Rubella Laboratory Network, January 2004–June 2005. MMWR Morb Mortal Wkly Rep 54:1100–1104Google Scholar
  9. Centers for Disease Control and Prevention (2007) Vaccination coverage among children in kindergarten – United States, 2006–07 school year. MMWR Morb Mortal Wkly Rep 56:819–821Google Scholar
  10. Centers for Disease Control and Prevention (2008a) Multistate measles outbreak associated with an international youth sporting event — Pennsylvania, Michigan, and Texas, August—September 2007. MMWR Morb Mortal Wkly Rep 57:169–173Google Scholar
  11. Centers for Disease Control and Prevention (2008b) Outbreak of measles — San Diego, California, January—February 2008. MMWR Morb Mortal Wkly Rep 57:203–206Google Scholar
  12. Centers for Disease Control and Prevention (2008c) Progress toward measles mortality reduction and elimination — Eastern Mediterranean Region, 1997–2007. MMWR Morb Mortal Wkly Rep 57:262–267Google Scholar
  13. Cohen JE (2003) Human population: the next half century. Science 302:1172–1175PubMedCrossRefGoogle Scholar
  14. Connolly MA, Gayer M, Ryan MJ, Salama P, Spiegel P, Heymann DL (2004) Communicable diseases in complex emergencies: impact and challenges. Lancet 364:1974–1983PubMedCrossRefGoogle Scholar
  15. Costa A, Henao-Restrepo AM, Hall SM, Jarrett S, Hoekstra EJ (2003) Determining measles-containing vaccine demand and supply: an imperative to support measles mortality reduction efforts. J Infect Dis 187 [Suppl 1]:S22–S28PubMedCrossRefGoogle Scholar
  16. Cutts FT, Steinglass R (1998) Should measles be eradicated? BMJ 316:765–767PubMedGoogle Scholar
  17. Dowdle WR, Hopkins DR (1998) The eradication of infectious diseases: report of the Dahlem Workshop on the eradication of infectious diseases, Berlin, March 16–22, 1997. Wiley, New Yo r kGoogle Scholar
  18. D'Souza RM, D'Souza R (2002) Vitamin A for the treatment of children with measles — a systematic review. J Trop Pediatr 48:323–327PubMedCrossRefGoogle Scholar
  19. Dayan GH, Cairns L, Sangrujee N, Mtonga A, Nguyen V, Strebel P (2004) Cost-effectiveness of three different vaccination strategies against measles in Zambian children. Vaccine 22:475–484PubMedCrossRefGoogle Scholar
  20. de Quadros CA (2004) Can measles be eradicated globally? Bull World Health Organ 82:134–138PubMedGoogle Scholar
  21. de Quadros CA, Olive JM, Hersh BS, Strassburg MA, Henderson DA, Brandling-Bennett D, Alleyne GA (1996) Measles elimination in the Americas. Evolving strategies. JAMA 275:224–229PubMedCrossRefGoogle Scholar
  22. de Quadros CA, Izurieta H, Venczel L, Carrasco P (2004) Measles eradication in the Americas: progress to date. J Infect Dis 189 [Suppl 1]:S227–S235PubMedCrossRefGoogle Scholar
  23. DeStefano F, Thompson WW (2004) MMR vaccine and autism: an update of the scientific evidence. Expert Rev Vaccines 3:19–22PubMedCrossRefGoogle Scholar
  24. Dine MS, Hutchins SS, Thomas A, Williams I, Bellini WJ, Redd SC (2004) Persistence of vaccine-induced antibody to measles 26–33 years after vaccination. J Infect Dis 189 [Suppl 1]: S123–S130PubMedCrossRefGoogle Scholar
  25. Duke T, Mgone CS (2003) Measles: not just another viral exanthem. Lancet 361:763–773PubMedCrossRefGoogle Scholar
  26. Dye C (2008) Health and urban living. Science 319:766–769PubMedCrossRefGoogle Scholar
  27. Feikin DR, Lezotte DC, Hamman RF, Salmon DA, Chen RT, Hoffman RE (2000) Individual and community risks of measles and pertussis associated with personal exemptions to immunization. JAMA 284:3145–3150PubMedCrossRefGoogle Scholar
  28. Frank SA, Bush RM (2007) Barriers to antigenic escape by pathogens: trade-off between reproductive rate and antigenic mutability. BMC Evol Biol 7:229PubMedCrossRefGoogle Scholar
  29. Gans HA, Arvin AM, Galinus J, Logan L, DeHovitz R, Maldonado Y (1998) Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA 280:527–532PubMedCrossRefGoogle Scholar
  30. Gay NJ (2004) The theory of measles elimination: implications for the design of elimination strategies. J Infect Dis 189 [Suppl 1]:S27–S35PubMedCrossRefGoogle Scholar
  31. Gomi H, Takahashi H (2004) Why is measles still endemic in Japan? Lancet 364:328–329PubMedCrossRefGoogle Scholar
  32. Gounder C (1998) The progress of the Polio Eradication Initiative: what prospects for eradicating measles? Health Policy Plan 13:212–233PubMedCrossRefGoogle Scholar
  33. Grais RF, Conlan AJ, Ferrari MJ, Djibo A, Le Menach A, Bjornstad ON, Grenfell BT (2008) Time is of the essence: exploring a measles outbreak response vaccination in Niamey, Niger. J R Soc Interface 5:67–74PubMedCrossRefGoogle Scholar
  34. Helfand RF, Moss WJ, Harpaz R, Scott S, Cutts F (2005) Evaluating the impact of the HIV pandemic on measles control and elimination. Bull World Health Organ 83:329–337PubMedGoogle Scholar
  35. Jansen VA, Stollenwerk N, Jensen HJ, Ramsay ME, Edmunds WJ, Rhodes CJ (2003) Measles outbreaks in a population with declining vaccine uptake. Science 301:804PubMedCrossRefGoogle Scholar
  36. Kamugisha C, Cairns KL, Akim C (2003) An outbreak of measles in Tanzanian refugee camps. J Infect Dis 187 [Suppl 1]:S58–S62PubMedCrossRefGoogle Scholar
  37. Katz SL (2006) Polio: new challenges in 2006. J Clin Virol 36:163–165PubMedCrossRefGoogle Scholar
  38. Low N, Kraemer S, Schneider M, Restrepo AM (2008) Immunogenicity and safety of aerosolized measles vaccine: systematic review and meta-analysis. Vaccine 26:383–398PubMedCrossRefGoogle Scholar
  39. Madsen KM, Hviid A, Vestergaard M, Schendel D, Wohlfahrt J, Thorsen P, Olsen J, Melbye M (2002) A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med 347:1477–1482PubMedCrossRefGoogle Scholar
  40. McQuillan GM, Kruszon-Moran D, Hyde TB, Forghani B, Bellini W, Dayan GH (2007) Seroprevalence of measles antibody in the US population, 1999–2004. J Infect Dis 196:1459–1464PubMedCrossRefGoogle Scholar
  41. Meissner HC, Strebel PM, Orenstein WA (2004) Measles vaccines and the potential for worldwide eradication of measles. Pediatrics 114:1065–1069PubMedCrossRefGoogle Scholar
  42. Monafo WJ, Haslam DB, Roberts RL, Zaki SR, Bellini WJ, Coffin CM (1994) Disseminated measles infection after vaccination in a child with a congenital immunodeficiency. J Pediatr 124:273–276PubMedCrossRefGoogle Scholar
  43. Morgan OW (2004) Following in the footsteps of smallpox: can we achieve the global eradication of measles? BMC Int Health Hum Rights 4:1PubMedCrossRefGoogle Scholar
  44. Moss WJ, Griffin DE (2006) Global measles elimination. Nat Rev Microbiol 4:900–908PubMedCrossRefGoogle Scholar
  45. Moss WJ, Cutts F, Griffin DE (1999) Implications of the human immunodeficiency virus epidemic for control and eradication of measles. Clin Infect Dis 29:106–112PubMedCrossRefGoogle Scholar
  46. Moss WJ, Monze M, Ryon JJ, Quinn TC, Griffin DE, Cutts F (2002) Prospective study of measles in hospitalized human immunodeficiency virus (HIV)-infected and HIV-uninfected children in Zambia. Clin Infect Dis 35:189–196PubMedCrossRefGoogle Scholar
  47. Moss WJ, Scott S, Mugala N, Ndhlovu Z, Beeler JA, Audet SA, Ngala M, Mwangala S, Nkonga-Mwangilwa, Ryon JJ, Monze M, Kasolo F, Quinn TC, Cousens S, Griffin DE, Cutts FT (2007) Immunogenicity of standard-titer measles vaccine in HIV-1-infected and uninfected Zambian children: an observational study. J Infect Dis 196:347–355PubMedCrossRefGoogle Scholar
  48. Offit PA, Coffin SE (2003) Communicating science to the public: MMR vaccine and autism. Vaccine 22:1–6PubMedCrossRefGoogle Scholar
  49. Orenstein WA, Strebel PM, Papania M, Sutter RW, Bellini WJ, Cochi SL (2000) Measles eradication: is it in our future? Am J Public Health 90:1521–1525PubMedCrossRefGoogle Scholar
  50. Otten M, Kezaala R, Fall A, Masresha B, Martin R, Cairns L, Eggers R, Biellik R, Grabowsky M, Strebel P, Okwo-Bele JM, Nshimirimana D (2005) Public-health impact of accelerated measles control in the WHO African Region 2000–03. Lancet 366:832–839PubMedCrossRefGoogle Scholar
  51. Pan American Health Organization (1999) Measles eradication. Field guide. Washington, DC, Pan American Health OrganizationGoogle Scholar
  52. Parker AA, Staggs W, Dayan GH, Ortega-Sanchez IR, Rota PA, Lowe L, Boardman P, Teclaw R, Graves C, LeBaron CW (2006) Implications of a 2005 measles outbreak in Indiana for sustained elimination of measles in the United States. N Engl J Med 355:447–455PubMedCrossRefGoogle Scholar
  53. Permar SR, Moss WJ, Ryon JJ, Monze M, Cutts F, Quinn TC, Griffin DE (2001) Prolonged measles virus shedding in human immunodeficiency virus-infected children, detected by reverse transcriptase-polymerase chain reaction. J Infect Dis 183:532–538PubMedCrossRefGoogle Scholar
  54. Salama P, Assefa F, Talley L, Spiegel P, van Der V, Gotway CA (2001) Malnutrition, measles, mortality, and the humanitarian response during a famine in Ethiopia. JAMA 286:563–571PubMedCrossRefGoogle Scholar
  55. Schimmer B, Ihekweazu C (2006) Polio eradication and measles immunisation in Nigeria. Lancet Infect Dis 6:63–65PubMedCrossRefGoogle Scholar
  56. Scott S, Moss WJ, Cousens S, Beeler JA, Audet SA, Mugala N, Quinn TC, Griffin DE, Cutts FT (2007) The influence of HIV-1 exposure and infection on levels of passively acquired antibodies to measles virus in Zambian infants. Clin Infect Dis 45:1417–1424PubMedCrossRefGoogle Scholar
  57. Scott S, Mossong J, Moss WJ, Cutts FT, Cousens S (2008) Predicted impact of the HIV-1 epidemic on measles in developing countries: results from a dynamic age-structured model. Int J Epidemiol 37:356–367PubMedCrossRefGoogle Scholar
  58. Sencer DJ, Dull HB, Langmuir AD (1967) Epidemiologic basis for eradication of measles in 1967. Public Health Rep 82:253–256PubMedGoogle Scholar
  59. Senessie C, Gage GN, von Elm E (2007) Delays in childhood immunization in a conflict area: a study from Sierra Leone during civil war. Confl Health 1:14PubMedCrossRefGoogle Scholar
  60. Stone R (2002) Smallpox. WHO puts off destruction of U.S., Russian caches. Science 295: 598–599PubMedCrossRefGoogle Scholar
  61. Takahashi H, Saito H (2008) Measles exportation from Japan to the United States, 1994 to 2006. J Travel Med 15:82–86PubMedCrossRefGoogle Scholar
  62. Tangermann RH, Hull HF, Jafari H, Nkowane B, Everts H, Aylward RB (2000) Eradication of poliomyelitis in countries affected by conflict. Bull World Health Organ 78:330–338PubMedGoogle Scholar
  63. Tejiokem MC, Gouandjika I, Beniguel L, Zanga MC, Tene G, Gody JC, Njamkepo E, Kfutwah A, Penda I, Bilong C, Rousset D, Pouillot R, Tangy F, Baril L (2007) HIV-infected children living in central Africa have low persistence of antibodies to vaccines used in the Expanded Program on Immunization. PLoS ONE:e1260Google Scholar
  64. United Nations, Department of Economic and Social Affairs Population Division (2007) World population prospects: the 2006 revision, highlights. United Nations, New YorkGoogle Scholar
  65. United Nations Population Fund (2007) State of the world population 2007: unleashing the potential of urban growth. United Nations Population FundGoogle Scholar
  66. Uzicanin A, Zhou F, Eggers R, Webb E, Strebel P (2004) Economic analysis of the 1996–1997 mass measles immunization campaigns in South Africa. Vaccine 22:3419–3426PubMedCrossRefGoogle Scholar
  67. Wakefield AJ, Murch SH, Anthony A, Linnell J, Casson DM, Malik M, Berelowitz M, Dhillon AP, Thomson MA, Harvey P, Valentine A, Davies SE, Walker-Smith JA (1998) Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 351:637–641PubMedCrossRefGoogle Scholar
  68. Wolfson LJ, Strebel PM, Gacic-Dobo M, Hoekstra EJ, McFarland JW, Hersh BS (2007) Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study. Lancet 369:191–200PubMedCrossRefGoogle Scholar
  69. Wolfson LJ, Gasse F, Lee-Martin SP, Lydon P, Magan A, Tibouti A, Johns B, Hutubessy R, Salama P, Okwo-Bele JM (2008) Estimating the costs of achieving the WHO-UNICEF Global Immunization Vision and Strategy, 2006–2015. Bull World Health Organ 86:27–39PubMedCrossRefGoogle Scholar
  70. World Health Organization (2004) Measles vaccines. Wkly Epidemiol Rec 79:130–142Google Scholar
  71. World Health Organization (2005) Progress in reducing measles mortality — worldwide 1999– 2003. Weekly Epidemiol Rec 80:78–81Google Scholar
  72. World Health Organization (2006a) Global distribution of measles and rubella genotypes — update. Wkly Epidemiol Rec 81:474–479Google Scholar
  73. World Health Organization (2006b) Impact of measles control activities in the WHO African Region, 1999–2005. Wkly Epidemiol Rec 81:365–371Google Scholar
  74. World Health Organization (2007a) Expanded Programme on Immunization of the Department of Immunization, Vaccines and Biologicals. WHO vaccine-preventable diseases: monitoring system. 2007 global summary. WHO/IVB/2007. World Health Organization, GenevaGoogle Scholar
  75. World Health Organization (2007b) Progress in global measles control and mortality reduction, 2000–2006. Wkly Epidemiol Rec. 82:418–424Google Scholar
  76. World Health Organization (2008) Immunization surveillance, assessment and monitoring. http:// www.who.int/immunization_monitoring/diseases/measles/en/. Cited 28 May 2008. World Health Organization, GenevaGoogle Scholar
  77. World Health Organization/United Nations Children's Fund (2001) Measles mortality reduction and regional elimination strategic plan 2001–2005. World Health Organization, GenevaGoogle Scholar
  78. World Health Organization/United Nations Children's Fund (2005) Global Immunization Vision and Strategy 2006–2015. World Health Organization, GenevaGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  1. 1.Department of Epidemiology and the W. Harry Feinstone Department of Molecular Microbiology and ImmunologyJohns Hopkins University Bloomberg School of Public HealthBaltimoreUSA

Personalised recommendations